貝達藥業(300558.SZ):甲磺酸貝福替尼一線治療適應症納入《國家醫保目錄》
格隆匯11月28日丨貝達藥業(300558.SZ)公佈,2024年11月28日,根據國家醫保局、人力資源社會保障部印發的《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄(2024年)〉的通知》【醫保發〔2024〕33號】,貝達藥業股份有限公司產品甲磺酸貝福替尼膠囊(賽美納®,以下簡稱“貝福替尼”)一線治療適應症納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2024年)》。
貝福替尼是第三代表皮生長因子受體酪氨酸激酶抑制劑(EGFR-TKI),是全新的、擁有自主知識產權的國家1類創新藥。本次納入醫保的為貝福替尼一線治療適應症,於2023年10月獲批上市。
公司產品鹽酸埃克替尼片(凱美納®)、鹽酸恩沙替尼膠囊(貝美納®)以及伏羅尼布片(伏美納?)均屬於國家醫保目錄協議期內談判藥品。同時,公司產品貝伐珠單抗注射液(貝安汀®)保留在國家醫保乙類藥品目錄。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.